MarketLens
Sign Up

Is Ionis Pharmaceuticals Poised for a Breakthrough with Tryngolza

7 months ago
SHARE THIS ON:

Is Ionis Pharmaceuticals Poised for a Breakthrough with Tryngolza

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•3 weeks ago

Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks

Ionis Pharmaceuticals highlighted TRYNGOLZA launch progress and regulatory wins at the Morgan Stanley conference, while acknowledging setbacks in late-stage cardiovascular studies.
Stock News•2 months ago

Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?

Ionis Pharmaceuticals director Hayden bought 20,000 shares for ~$1.1 million, raising his direct and indirect holdings by 34%, signaling insider confidence.
Stock News•3 months ago

Can Biogen Score Another Win In Alzheimer's Disease?

Biogen and Ionis' tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over 18 months, potentially adding a new therapy to Biogen's pipeline after its earlier Aduhelm struggles.

Breaking News

View All →

Top Headlines

View More →
Stock News•1 hour ago

Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today

Stock News•1 hour ago

Why the Market Dipped But Microsoft (MSFT) Gained Today

Stock News•1 hour ago

Nvidia (NVDA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Stock News•1 hour ago

Tesla (TSLA) Declines More Than Market: Some Information for Investors

Stock News•1 hour ago

Amazon Will Be The Final Winner Of The AI Race With Anthropic's Help